Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 29, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Tumor Lysis Syndrome Clear all

Conditions: Tumor Lysis Syndrome
Interventions: urate oxidase; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Leukemia, Lymphoma, Tumor Lysis Syndrome, Hyperuricemia
Interventions: Rasburicase; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Palo Alto, California • San Diego, California • Indianapolis, Indiana + 8 more

Conditions: Tumor Lysis Syndrome, Cancer, Hyperuricemia
Interventions: Rasburicase (SR29142), Allopurinol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 15
States / cities: Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions: Rasburicase (SR29142); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Leukemia, Lymphoma
Interventions: Rasburicase, Allopurinol; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia
Interventions: Venetoclax, Acalabrutinib, Obinutuzumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 32
States / cities: Tucson, Arizona • Clovis, California • Los Angeles, California + 28 more

Conditions: Lymphoma
Interventions: Flavopiridol; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Leukemia, Lymphoma, Tumor Lysis Syndrome
Interventions: Rasburicase; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tumor Lysis Syndrome
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 2 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Valhalla, New York • Oklahoma City, Oklahoma • Memphis, Tennessee + 1 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Interventions: Obinutuzumab, Bendamustine, Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 15
States / cities: Tempe, Arizona • Denver, Colorado • Kansas City, Missouri + 12 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Tumor Lysis Syndrome
Interventions: Pegloticase, Rasburicase; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors, Lymphoma, Multiple Myeloma, Hematologic Malignancies
Interventions: AZD0466; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: No City Provided, New Jersey

Conditions: Tumor Lysis Syndrome
Interventions: As Needed Rasburicase, Fixed Dose Rasburicase; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Fasturtec TLS Treatment / Prophylysis

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS

Elitek (Rasburicase) Immuno-Monitoring Study

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg

Rasburicase in Patients at Risk for Tumor Lysis Syndrome